Results 171 to 180 of about 3,283 (198)

Short-Term Outcomes of Faricimab Treatment in Aflibercept-Refractory Eyes with Neovascular Age-Related Macular Degeneration

Journal of Clinical Medicine, 2023
To evaluate the functional and anatomical effects of switching to faricimab for patients with neovascular age-related macular degeneration (nAMD) refractory to intravitreal aflibercept, this retrospective study evaluated patients with nAMD who received ...
Hisanori Imai, Sentaro Kusuhara, Makoto Nakamura   +2 more
exaly   +2 more sources

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

Lancet, The, 2022
Sean D Adrean, Geeta Menon, Charles C Wykoff   +2 more
exaly   +2 more sources

Real-World Evidence for Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Scoping Review

Ophthalmology Science
Purpose Since faricimab (Vabysmo) was approved for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), a growing body of real-world data has been reported, forming an important source of evidence for ...
Rishi P Singh, Varun Chaudhary
exaly   +2 more sources

Switch to faricimab after initial treatment with aflibercept in eyes with diabetic macular edema

International Ophthalmology
PURPOSE: To assess the effectiveness of a switch to faricimab in individuals affected by DME and previously treated with aflibercept. METHODS: In this retrospective, single-center study, DME patients previously treated with at least 3 injections of ...
Francesco Pichi, Aniruddha Agarwal, Shaikha Aljneibi   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Outcomes and predictive factors for fluid resolution following three loading injections of faricimab for treatment-naïve neovascular age-related macular degeneration

Scientific Reports
To evaluate the outcomes and predictive factors for fluid resolution following three loading injections of faricimab for neovascular age-related macular degeneration(AMD).
Hee-Yong Han, Sang Min Park, Ji Hyun Lee, C. Kim, Jong Woo Kim, H. Cho, Jae Hui Kim   +6 more
semanticscholar   +1 more source

Switching to Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: Initial Real-World Efficacy Outcomes

Journal of Clinical Medicine
Background/Objectives: Macular edema (ME), due to retinal vein occlusion (RVO), is a major cause of vision impairment. Many patients experience suboptimal responses to anti-vascular endothelial growth factor (anti-VEGF) monotherapy, necessitating ...
M. Hafner, T. Herold, Alexander Kufner, Ben Asani, Andreas Anschütz, Franziska Eckardt, Siegfried G. Priglinger, J. Schiefelbein   +7 more
semanticscholar   +1 more source

INTRAOCULAR INFLAMMATION ASSOCIATED WITH FARICIMAB THERAPY

Retina
In this real-world report, faricimab was well tolerated with a low incidence of intraocular inflammation. Purpose: To report 1-year real-world evidence on intraocular inflammation (IOI) adverse events in patients undergoing faricimab therapy in a ...
Andrea Montesel, S. Sen, Ella Preston, Praveen J. Patel, Josef Huemer, Robin D. Hamilton, L. Nicholson, Ioannis Papasavvas, William R. Tucker, Ian Yeung   +9 more
semanticscholar   +1 more source

Inflammation and Occlusive Retinal Vasculitis Post Faricimab.

JAMA ophthalmology
Importance Randomized clinical trials have shown the safety and efficacy of faricimab as a novel vascular endothelial growth factor and angiopoietin-2 inhibitor in the treatment of neovascular age-related macular degeneration (nAMD) and macular edema of ...
Will Bruening, Sean Kim, Steven Yeh, Pukhraj Rishi, Christopher D. Conrady   +4 more
semanticscholar   +1 more source

One-year functional and structural results of faricimab for treatment-naïve neovascular age related macular degeneration: An OCT angiography study

Graefe's Archive for Clinical and Experimental Ophthalmology
To explore the 1-year functional and anatomic outcomes of treatment-naïve neovascular age-related macular degeneration (nAMD) eyes undergoing a treat and extend (TAE) regimen with faricimab, Prospective interventional study on 33 eyes with treatment ...
Alessandra Scampoli, Matteo Mario Carlà, Giulia Grieco, Lorenzo Governatori, Roberta Catalani, S. Rizzo, T. Caporossi   +6 more
semanticscholar   +1 more source

IMPACT OF FARICIMAB VERSUS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN PATIENTS WITH DIABETIC MACULAR EDEMA IN THE PHASE 3 YOSEMITE AND RHINE TRIALS

Retina
Supplemental Digital Content is Available in the Text. Post hoc analysis of phase 3 YOSEMITE/RHINE trials found that intravitreal faricimab every 8 weeks (Q8W) for 2 years reduced epiretinal membrane (ERM) formation in eyes with diabetic macular edema ...
Glenn J. Jaffe, G. Deák, K. Gibson, Rahul N. Khurana, E. Nudleman, Yuichiro Ogura, Ursula Schmidt-Erfurth, Tracey Wang, Peter D. Westenskow, David T. Wong, G. Yiu, Jeffrey R. Willis   +11 more
semanticscholar   +1 more source